Drug data · shortage, price, volume

Valsartan tablets: listed 19 months as a shortage, and the generic benchmark price fell 59% since 2021

The FDA has listed this drug as short in the past. The pharmacy benchmark says the generic tablet now costs $0.100 each, against $2.61 in 2014. Availability and price are different measures, so this page shows both over time.

FDA shortage list, 2026-11-05NADAC, November 2026Medicaid SDUDinferred monthno data
  1. The tablet was on the FDA list from September 2018 to March 2020, 19 months, and is not listed now.
  2. 53% of shortage listings since 2014 lasted as long as this one. The median lasts 21 months.
  3. A generic 40 mg tablet costs pharmacies $0.100 on the NADAC benchmark in November 2026, 59% below its 2021 median.
  4. The brand Diovan tablet is $7.82 each, about 78 times the generic.
  5. Medicaid paid for 160,695 tablet prescriptions in Q4 2025, 58% more than in Q4 2021.

Not medical advice. This page reports public records about supply and pharmacy cost. Ask a pharmacist or prescriber about your own medication.

Three clocks on one timeline

Each lane uses the same monthly axis, so you can read across: when the FDA listed the tablet, what pharmacies were paying, and how many Medicaid prescriptions were filled.

on the listinferred across a missing captureno capture or no price$ per tabletprescriptionspreliminary quarter

Swipe the chart sideways to see all 14 years.

Three clocks: FDA shortage list, pharmacy acquisition cost and Medicaid prescriptionsShared monthly timeline. Top lane: months the tablet was on the FDA shortage list. Middle lane: NADAC price per tablet by strength. Bottom lane: Medicaid prescriptions per quarter. 2014201520162017201820192020202120222023202420252026FDA shortage listtablet, by name2013-01 to 2014-05: no capture of the FDA list for these months2014-09 to 2014-09: no capture of the FDA list for these months2016-02 to 2016-02: no capture of the FDA list for these months2018-09 to 2018-09: on the list (observed)2018-10 to 2018-11: on the list (inferred across a missing capture)2018-12 to 2019-01: on the list (observed)2019-02 to 2019-04: on the list (inferred across a missing capture)2019-05 to 2020-03: on the list (observed)2024-10 to 2025-08: no capture of the FDA list for these monthsfirst listed Sep 2018Pharmacy costNADAC, $ per tabletbold = 40 mg generic$0$2.5$5$2.61 in 2014$0.100 nowMedicaid fillsprescriptions per quartertablet2013Q1: 112,905 prescriptions; unsuppressed state rows only2013Q2: 108,940 prescriptions; unsuppressed state rows only2013Q3: 103,170 prescriptions; unsuppressed state rows only2013Q4: 96,269 prescriptions; unsuppressed state rows only2014Q1: 89,592 prescriptions; unsuppressed state rows only2014Q2: 93,804 prescriptions; unsuppressed state rows only2014Q3: 71,082 prescriptions; unsuppressed state rows only2014Q4: 61,148 prescriptions; unsuppressed state rows only2015Q1: 61,071 prescriptions; unsuppressed state rows only2015Q2: 65,223 prescriptions; unsuppressed state rows only2015Q3: 68,563 prescriptions; unsuppressed state rows only2015Q4: 64,992 prescriptions; unsuppressed state rows only2016Q1: 79,161 prescriptions; unsuppressed state rows only2016Q2: 82,942 prescriptions; unsuppressed state rows only2016Q3: 87,466 prescriptions; unsuppressed state rows only2016Q4: 100,872 prescriptions; unsuppressed state rows only2017Q1: 102,817 prescriptions; unsuppressed state rows only2017Q2: 113,396 prescriptions; unsuppressed state rows only2017Q3: 109,323 prescriptions; unsuppressed state rows only2017Q4: 112,659 prescriptions; unsuppressed state rows only2018Q1: 120,930 prescriptions; unsuppressed state rows only2018Q2: 127,744 prescriptions; unsuppressed state rows only2018Q3: 55,965 prescriptions; unsuppressed state rows only2018Q4: 35,265 prescriptions; unsuppressed state rows only2019Q1: 38,833 prescriptions; unsuppressed state rows only2019Q2: 50,916 prescriptions; unsuppressed state rows only2019Q3: 58,529 prescriptions; unsuppressed state rows only2019Q4: 68,716 prescriptions; unsuppressed state rows only2020Q1: 77,490 prescriptions; unsuppressed state rows only2020Q2: 72,138 prescriptions; unsuppressed state rows only2020Q3: 75,510 prescriptions; unsuppressed state rows only2020Q4: 77,085 prescriptions; unsuppressed state rows only2021Q1: 80,752 prescriptions; unsuppressed state rows only2021Q2: 87,166 prescriptions; unsuppressed state rows only2021Q3: 94,798 prescriptions; unsuppressed state rows only2021Q4: 101,739 prescriptions; unsuppressed state rows only2022Q1: 112,433 prescriptions; unsuppressed state rows only2022Q2: 121,309 prescriptions; unsuppressed state rows only2022Q3: 128,825 prescriptions; unsuppressed state rows only2022Q4: 127,288 prescriptions; unsuppressed state rows only2023Q1: 137,275 prescriptions; unsuppressed state rows only2023Q2: 137,194 prescriptions; unsuppressed state rows only2023Q3: 140,844 prescriptions; unsuppressed state rows only2023Q4: 132,127 prescriptions; unsuppressed state rows only2024Q1: 137,762 prescriptions; unsuppressed state rows only2024Q2: 136,710 prescriptions; unsuppressed state rows only2024Q3: 146,761 prescriptions; unsuppressed state rows only2024Q4: 146,277 prescriptions; unsuppressed state rows only2025Q1: 149,642 prescriptions; unsuppressed state rows only2025Q2: 152,057 prescriptions; unsuppressed state rows only2025Q3: 160,795 prescriptions; unsuppressed state rows only2025Q4: 160,695 prescriptions; unsuppressed state rows only2026Q1: 148,311 prescriptions (latest quarter, preliminary: CMS may revise); unsuppressed state rows only161k0
Top: months the tablet name was on the FDA list (Wayback captures of the FDA page; the current FDA record says posted 2025-11-19). Middle: NADAC per tablet, one line per strength. Bottom: Medicaid prescriptions per quarter. Medicaid volume: 85,592 rows pulled for this drug, 44,762 (52%) suppressed by CMS for small cells and left out, never counted as zero, so every bar is a floor; state XX national rows excluded; the hatched latest quarter is preliminary. Fills also move with Medicaid enrollment, so a change is not by itself evidence of a shortage.

How long do shortages last?

Each step is a drop in the share of FDA shortage listings still running. The dot is this drug.

Share of FDA shortage listings still running after N months, with this drug marked0%25%50%75%100%024487296120months on the FDA listmedian 21 monthsthis listing (ended): 19 mo53% lasted this long
Kaplan-Meier on 397 listings, 2014 to 2026, by ingredient. 18 months have no capture and are bridged by inference. Every listing behind this curve, with the method and a dated correction, is in the shortage length dataset.

What a pharmacy pays per unit

NADAC is the average price retail pharmacies pay, per tablet.

Pharmacy acquisition cost per unit, brand against genericBrand tablet (Diovan 40 mg)$7.82Generic tablet (40 mg, median)$0.100
Thirty generic 40 mg tablets is about $3.00 at this benchmark. It is acquisition cost, not a retail price.

Which forms are short

FDA listing by dosage form
FormListed nowMonths listedFDA records (2026-11-05)
tabletNo (last listed March 2020)19 (4 records)

Price by strength

Tablet: generic acquisition cost per tablet by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
40 mg$0.100$0.242$2.612014-09-59%18
80 mg$0.081$0.241$3.082014-09-67%17
160 mg$0.106$0.283$3.362014-09-63%18
320 mg$0.170$0.392$4.182014-09-57%14
Tablet: brand (Diovan) acquisition cost per tablet by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
40 mg$7.82n/a$3.192013-11n/a31-month gap in NADAC reporting1 (single product, not a median)
80 mg$9.33$7.52$3.802013-11+24%1 (single product, not a median)
160 mg$10.04$8.15$4.092013-11+23%1 (single product, not a median)
320 mg$12.69$10.28$5.182013-11+23%1 (single product, not a median)
Read the price with care. NADAC is a national survey average of retail pharmacy invoices. It is not a quote, not what any patient paid, and it excludes discounts and rebates. A flat or falling benchmark during a shortage means pharmacies' average invoice cost did not rise, not that every patient could find the drug at that price.
FDA caution. The FDA drug shortage list is updated as manufacturers report and should not be relied on for medical care. Ask a pharmacist or prescriber about supply.

Questions

Is Valsartan still in shortage?

The tablet is not on the FDA shortage list as of 2026-11-05. It was listed from September 2018 to March 2020. FDA says not to rely on the list for medical care; ask a pharmacist.

Did the shortage raise the pharmacy price?

Not in the benchmark. The NADAC survey average for a generic 40 mg tablet is $0.100 in November 2026, 59% below its 2021 median and 96% below September 2014. NADAC is a national average of retail pharmacy invoices, so it measures what pharmacies pay on average, not what any one patient was charged.

Did Medicaid fills fall during the shortage?

No. CMS State Drug Utilization Data shows 160,695 Medicaid-paid tablet prescriptions in Q4 2025, 58% more than in Q4 2021 (101,739). Those counts are a floor because CMS suppresses small cells, they cover Medicaid only and move with Medicaid enrollment, and they count prescriptions that were filled, not demand that went unmet. A change in fills is not by itself evidence of a shortage.

What does a pharmacy pay for 30 generic 40 mg tablets?

About $3.00 on the NADAC benchmark ($0.100 per tablet times 30). That is acquisition cost, not a retail price: it excludes dispensing fees, discounts and rebates.

If you are trying to pay for or find this drug

Run a pharmacy, discount card, telehealth or assistance service that helps people pay for medicines? Apply to be evaluated for a page like this one, or hold a disclosed featured slot. Inclusion is earned. A slot is labelled sponsored and never implies a medical endorsement. Building a product on this data? Licence the widget or the data feed.

Cite this page

Figures are calculated from U.S. federal sources (see Data terms below) and rebuilt from dated snapshots. Cite it as:

OmniRx, "Valsartan: FDA shortage, NADAC acquisition cost and Medicaid utilization", data as of November 2026. https://omnirx.org/drugs/valsartan

Embed this chart

Free with attribution: paste this where you want the chart. It sizes itself to its content. A small "Powered by OmniRx" link stays in the widget; white-label licences remove it and add your own branding.

<iframe id="lx-drug-valsartan" src="https://omnirx.org/embed/drug-valsartan" width="100%" height="640" style="border:1px solid #e2e8f0;border-radius:10px" title="Valsartan shortage and price timeline by omnirx.org" loading="lazy"></iframe>
<script>addEventListener('message',function(e){if(e.origin!=='https://omnirx.org')return;var d=e.data||{};if(d.type==='lx-height'&&d.slug==='drug-valsartan'){var f=document.getElementById('lx-'+d.slug);if(f)f.height=d.height;}});</script>

Sources

Data terms. Every source above is published by a U.S. federal agency (CMS or FDA). CMS's data site labels its datasets inconsistently: of the 14 NADAC years, 5 carry the "public domain" label and 9 the "U.S. government works" label; of the 14 State Drug Utilization Data years, 6 carry the "public domain" label and 8 the "U.S. government works" label. We record each dataset's label verbatim and cite the source for every figure. Figures on this page are OmniRx calculations from those datasets, not statements by CMS or FDA, and no agency endorses this page.